As mechanism of action, JAM-A overexpression selectively activated transforming growth factor-β (TGF-β)/NODAL signaling, thereby enhancing B lymphoma cell aggressiveness and inducing extranodal involvement to mesoendoderm-derived organs in DLBCL. The gene discussed is TGFB1; the disease is diffuse large B-cell lymphoma.